

Journal of Hepatology

CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

| |
|--|
| |
|--|

1.1 Antibodies

| Name | Citation | Supplier | Cat no. | Clone no. |
|-------|---|---|------------------------|------------|
| PD-L1 | I-Khoueiry, et al. Lancet 2017;389:2492-2502. | Dako, an Agilent Technologies, Inc. company | PD-L1 IHC 28-8 pharmDx | clone 28-8 |

1.2 Cell lines

| Name | Citation | Supplier | Cat no. | Passage no. | Authentication test method |
|----------------|----------|----------|---------|-------------|----------------------------|
| Not applicable | | | | | |

1.3 Organisms

| Name | Citation | Supplier | Strain | Sex | Age | Overall n number |
|----------------|----------|----------|--------|-----|-----|------------------|
| Not applicable | | | | | | |

1.4 Sequence based reagents

| Name | Sequence | Supplier |
|----------------|----------|----------|
| Not applicable | | |

1.5 Biological samples

| Description | Source | Identifier |
|----------------|--------|------------|
| Not applicable | | |

1.6 Deposited data

| Name of repository | Identifier | Link |
|--------------------|------------|------|
| Not applicable | | |

1.7 Software

| Software name | Manufacturer | Version |
|---------------|--------------------|---------|
| SAS | SAS Institute Inc. | 9.3 |

1.8 Other (e.g. drugs, proteins, vectors etc.)

| | | |
|-----------|--|--|
| Nivolumab | | |
| | | |

1.9 Please provide the details of the corresponding methods author for the manuscript:

Thomas Yau

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

Clinical protocol included in the submission, redacted of information from other cohorts not reported on in the manuscript and any patient sensitive/proprietary information